Mark C Totoritis

US Patent:

20140017261, Jan 16, 2014

Filed:

Feb 2, 2012

Appl. No.:

13/981699

Inventors:

Mark Totoritis - Rancho Santa Fe CA, US

International Classification:

A61K 39/395
A61K 33/24
A61K 31/655
A61K 31/4706
A61K 31/519
A61K 31/42

US Classification:

4241721, 435 39

Abstract:

The invention relates to methods of selecting a subject, and methods of treating the subject with an anti-VLA-1 antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug), such as gold salts; hydroxychloroquine; an antifolate, such as methotrexate; a pyrimidine synthesis inhibitor, such as leflunomide; or a sulfa drug, such as sulfasalazine. For example, the DMARD can be methotrexate, administered at a dose of mg/week or less; leflunomide, administered at a dose of 20 mg/day or less; sulfasalazine, administered at a dose of 3000 mg/day or less; or hydroxychloroquine, administered at a dose of 400 mg/day or less.

US Patent:

20090238762, Sep 24, 2009

Filed:

Nov 14, 2006

Appl. No.:

11/665525

Inventors:

Mark Totoritis - Rancho Santa Fe CA, US
Timothy Mark Shaw - Hertfordshire, GB
Sunil Agarwal - Corte Madera CA, US
David Yocum - San Mateo CA, US
Ariella Kelman - Hillsborough CA, US

International Classification:

A61K 39/395
A61P 19/02
A61P 37/00
A61B 10/00

US Classification:

424 92, 4241331

Abstract:

Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.

US Patent:

20160361394, Dec 15, 2016

Filed:

Feb 27, 2015

Appl. No.:

15/122130

Inventors:

- Raleigh NC, US
Mark C. Totoritis - Rancho Santa Fe CA, US

Assignee:

Santarus, Inc. - Raleigh NC

International Classification:

A61K 38/57
A61K 9/00

Abstract:

A method for treating acute attacks of hereditary angioedema (HAE) whereby a first does and a second dose of a recombinant C1 esterase inhibitor is administered intravenously to the patient, each dose at 50 IU/kg body weight of the patient and wherein the first and second doses are administered within a 24 hour period. The recombinant C1 esterase inhibitor has an amino acid sequence identical to the amino acid sequence of human plasma-derived C1 esterase inhibitor and a modified carbohydrate structure as compared to the human plasma-derived C1 esterase inhibitor. Relief of attack symptoms as well as reduction of relapse and/or new attack symptoms are achieved by use of the method.

US Patent:

20160340433, Nov 24, 2016

Filed:

Aug 4, 2016

Appl. No.:

15/228711

Inventors:

- Bridgewater NJ, US
Mark Totoritis - Rancho Santa Fe CA, US

International Classification:

C07K 16/28
A61K 31/655
A61K 31/4706
A61K 31/519
A61K 39/395
A61K 31/42

Abstract:

The invention relates to methods of selecting a subject, and methods of treating the subject with an anti-VLA-1 antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug), such as gold salts; hydroxychloroquine; an antifolate, such as methotrexate; a pynmidine synthesis inhibitor, such as leflunomide; or a sulfa drug, such as sulfasalazine. For example, the DMARD can be methotrexate, administered at a dose of mg/week or less; leflunomide, administered at a dose of 20 mg/day or less; sulfasalazine, administered at a dose of 3000 mg/day or less; or hydroxychloroquine, administered at a dose of 400 mg/day or less.